MA37437B1 - Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement - Google Patents

Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement

Info

Publication number
MA37437B1
MA37437B1 MA37437A MA37437A MA37437B1 MA 37437 B1 MA37437 B1 MA 37437B1 MA 37437 A MA37437 A MA 37437A MA 37437 A MA37437 A MA 37437A MA 37437 B1 MA37437 B1 MA 37437B1
Authority
MA
Morocco
Prior art keywords
choice
status
treatment
her2 protein
breast cancer
Prior art date
Application number
MA37437A
Other languages
English (en)
Other versions
MA37437A1 (fr
Inventor
El Hassane Sefrioui
Abdeladim MOUMEN
El Amrani Manal
Imane Abdellaoui-Maane
Hadi Hicham El
Original Assignee
Mascir (Morrocan Found For Advanced Science Innovation & Research)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mascir (Morrocan Found For Advanced Science Innovation & Research) filed Critical Mascir (Morrocan Found For Advanced Science Innovation & Research)
Priority to MA37437A priority Critical patent/MA37437B1/fr
Priority to PCT/MA2015/000018 priority patent/WO2016060536A1/fr
Publication of MA37437A1 publication Critical patent/MA37437A1/fr
Publication of MA37437B1 publication Critical patent/MA37437B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un kit de diagnostic in vitro pour la quantification des transcrits du gène her2 surexprimé dans le cas du cancer du sein et de l’estomac ainsi que dans d’autres types de cancers. Le présent kit est composé d’une combinaison innovante de nouveaux sets d’amorces et de sondes permettant la détection spécifique et la quantification des transcrits du gène her2 et les gènes de référence, choisis parmi les gènes rpl30 ou rpl37 ou bien mrpl19 en utilisant la méthode de transcription inverse-pcr en temps réel (rtqpcr) en format multiplexe ou simplexe. Le présent kit est destiné pour l’établissement du statut de la protéine her2 et le choix du traitement pour le cancer de sein ou tout cancer nécessitant une quantification de la protéine her2.
MA37437A 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement MA37437B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MA37437A MA37437B1 (fr) 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement
PCT/MA2015/000018 WO2016060536A1 (fr) 2014-10-17 2015-10-17 Kit de diagnostic du cancer de sein en reaction qpcr multiplex et son application dans l'evaluation du statut de la proteine her2 et le choix du traitement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA37437A MA37437B1 (fr) 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement

Publications (2)

Publication Number Publication Date
MA37437A1 MA37437A1 (fr) 2016-05-31
MA37437B1 true MA37437B1 (fr) 2016-12-30

Family

ID=55273425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37437A MA37437B1 (fr) 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement

Country Status (2)

Country Link
MA (1) MA37437B1 (fr)
WO (1) WO2016060536A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41742B1 (fr) * 2017-12-29 2020-02-28 Moroccan Foundation For Advanced Science Innovation And Res Mascir Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers.
RU2701356C1 (ru) * 2018-09-18 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ диагностики рака молочной железы с экспрессией рецептора Her2/neu на мембране опухолевых клеток
CN110616251B (zh) * 2019-09-29 2022-08-05 中国计量科学研究院 一种用于检测乳腺癌her2拷贝数变异的数字pcr方法及检测试剂盒
CN117995279B (zh) * 2024-04-03 2024-06-18 四川大学华西医院 不同pcr仪器间定量或定性检测结果同质化换算方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA35294B1 (fr) * 2012-12-27 2014-08-01 Mascir Moroccan Foundation For Advanced Science Innovation & Res Sondes et amorces pour detecter le gene her2 en format multiplexe et ses applications dans le choix du traitement du cancer de sein her2

Also Published As

Publication number Publication date
WO2016060536A1 (fr) 2016-04-21
MA37437A1 (fr) 2016-05-31

Similar Documents

Publication Publication Date Title
El-Mogy et al. Diversity and signature of small RNA in different bodily fluids using next generation sequencing
Koumangoye et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells
Chu et al. Identification of novel piRNAs in bladder cancer
MA37437B1 (fr) Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement
Ismail et al. Diagnostic significance of miR-639 and miR-10b in βreast cancer patients
Chen et al. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells
MX2017014859A (es) Metodos y composiciones para diagnosticar o detectar canceres de pulmon.
Yin et al. Small RNA sequencing revealed aberrant piRNA expression profiles in colorectal cancer
AU2003294447A8 (en) Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
Wennemers et al. Regulation of TRIB3 mRNA and protein in breast cancer
Kaehler et al. MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells
Ravid et al. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures
Huang et al. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas
WO2018096375A3 (fr) Méthode de détermination de l'état réceptif de l'endomètre
Li et al. Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
Hamborg et al. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
CA2978368C (fr) Signature de la sante
ES2736850T3 (es) Detección de moléculas de ácido nucleico
MA20150144A1 (fr) Kit de diagnostic de la leucemie myeloide chronique en reaction multiplex et ses applications dans le suivi du traitement et de la maladie residuelle
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
Tsai et al. Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target
TN2015000292A1 (fr) Sondes et amorces pour detecter le gene her2 et un gene (ribosomale) de controle en format multiplex : applications dans le choix de traitement du cancer de sein her2
MA30565B1 (fr) Procede de diagnostic et traitement anticancereux